Creative Proteomics provides N-terminal sequence analysis by both Edman and Mass spectrometry of therapeutic proteins, monoclonal antibodies and protein vaccines.In protein N-terminal sequence analysis, proteins are first modified with phenylisothiocyanate (PITC). Subsequently, the derivatized terminal amino acid is removed by acid cleavage in a form of phenylthiohydantoin (PTH) derivative and a new α-amino group on the next amino acid is now available for the next round of reaction with PITC. Protein sequence is therefore being analyzed in through a serious reaction of PITC addition, and cleavage of one PTH at each time for analysis. Suppose the reactions are fully efficient, this method can sequence the whole amino acid from the N-terminal end. Though less efficient as compared with mass spectrometer, N-terminal Edman sequencing still has advantages for protein analysis that cannot readily be obtained by other analysis methods. With current technology, it is fairly routine to obtain at least 20 to 25 residues of sequence from the N-terminus of the proteins and peptides.